{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/smoking-cessation/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"8e76eb05-e3c6-56ff-9af2-254532c75b13","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 91582054-eef3-46f3-8e29-459431b01bdc --><h2>Changes</h2><!-- end field 91582054-eef3-46f3-8e29-459431b01bdc -->","summary":null,"htmlStringContent":"<!-- begin item 0340041d-6d19-480a-96d1-05c356434864 --><!-- begin field 7a1d0b95-a7fd-4db4-a296-8a85791bc554 --><p><strong>November 2020 </strong>— minor update. Risk of serotonin syndrome if selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors are taken concurrently with bupropion has been added in line with updated manufacturer's SPC.</p><p><strong>March 2018</strong> — reviewed. A literature search was conducted in February to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. There have been minor structural changes to the topic and information on Very Brief Advice on smoking cessation for adults and pregnant women, and recommendations regarding e-cigarettes have been added.</p><!-- end field 7a1d0b95-a7fd-4db4-a296-8a85791bc554 --><!-- end item 0340041d-6d19-480a-96d1-05c356434864 -->","topic":{"id":"ebf6cee5-5af1-52b6-be36-ffbde79ca62f","topicId":"d067f8f3-0954-4f6f-aa2d-7367538e4d66","topicName":"Smoking cessation","slug":"smoking-cessation","lastRevised":"Last revised in November 2020","chapters":[{"id":"0061c5ae-dd4a-5d21-b48c-668fde7b2792","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6d1d5418-f561-5af6-b8c6-fc662f3ed1a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4153a516-b9c3-5ccd-b0dc-802eec6e791e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e76eb05-e3c6-56ff-9af2-254532c75b13","slug":"changes","fullItemName":"Changes"},{"id":"3c6ceb58-b810-5e70-839f-8509aaafe066","slug":"update","fullItemName":"Update"}]},{"id":"ea4cf1db-781d-5517-8878-d38a96f2d1c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bbbe94e2-fe22-5d1a-acb7-68d5e9889beb","slug":"goals","fullItemName":"Goals"},{"id":"56f5ea28-1670-53a4-a478-33a402bc7d1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"234b7e6d-ac08-55b2-abd7-674c4643c59c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d2e91021-4127-5bfa-9129-033bc40bcab8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e030910-df21-55ed-85f4-778b0a92a88f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"583a3a07-c973-5d68-b342-99b8e0dbeb74","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8349892f-8857-507e-b3ca-b3aedf9ff29d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"22c82094-eeb9-578d-acb1-a91b122b264b","slug":"withdrawal-symptoms","fullItemName":"Withdrawal symptoms"},{"id":"684b949d-de54-55c1-9c8c-5e29f240784d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"de278e39-c963-55cb-b3f3-f4c21c4bce92","slug":"harms-caused-by-smoking","fullItemName":"Harms caused by smoking"},{"id":"a9f396cb-609a-5ab8-b6ad-24d7084af5f5","slug":"benefits-of-stopping-smoking","fullItemName":"Benefits of stopping smoking"}]},{"id":"d491264b-2fec-55fc-8464-dc497057057c","fullItemName":"Management","slug":"management","subChapters":[{"id":"67f11ceb-acb3-546c-ba55-c7981861e6bb","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"6593a229-0a53-5e7e-94df-52f7ea3e248d","slug":"adults","fullItemName":"Scenario: Adults"},{"id":"e616e0e0-2ef7-55fb-b0a5-40a1dee23996","slug":"pregnant-or-breastfeeding","fullItemName":"Scenario: Pregnant or breastfeeding"},{"id":"39b9fd08-1dfb-5cff-a105-6964621414fc","slug":"12-17-years","fullItemName":"Scenario: 12-17 years"},{"id":"1521b61b-1fc1-505a-b1ea-4f3c6c7821e5","slug":"harm-reduction","fullItemName":"Scenario: Harm reduction"}]},{"id":"534878c5-24a6-5d55-aab1-d680da731f9c","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5385fc41-730b-5f44-b19a-162c234ba090","slug":"nicotine-replacement-therapy-nrt","fullItemName":"Nicotine replacement therapy (NRT)"},{"id":"029422cb-c063-54a5-adba-d7e2c1508a2c","slug":"bupropion","fullItemName":"Bupropion"},{"id":"0bf318c3-08dc-5d92-a4d3-2a76e6dcacff","slug":"varenicline","fullItemName":"Varenicline"},{"id":"55631955-d4e3-58ea-92ab-c9beb61af299","slug":"drugs-affected-by-smoking-cessation","fullItemName":"Drugs affected by smoking cessation"}]},{"id":"08f5d42d-b8f6-5145-bef7-f1049e7b6e47","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dd871a8-f5c2-5399-bbd0-e38843de9929","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"54db5fa3-0428-5365-9b73-16348c0cbc3f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7af0460f-945a-59a6-9b1a-583aab3c09b8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fe134945-3412-53ed-b798-57e958ac842c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d8a134c7-4e7c-5c14-a053-831f057b4fac","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"42f0adc0-ab3c-5a96-b5a6-0eb20614a611","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"07a973a1-96be-50d1-9ff8-17e6396e0d13","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4153a516-b9c3-5ccd-b0dc-802eec6e791e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"6278da92-0eba-5282-b6b8-4362ecb057c0","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 79ec8ab6-2af2-499a-953e-f82e38eed351 --><h3>Previous changes</h3><!-- end field 79ec8ab6-2af2-499a-953e-f82e38eed351 -->","summary":null,"htmlStringContent":"<!-- begin item 9075f2c2-0a4d-4f46-9de3-783a3862f4a8 --><!-- begin field eb1c9020-21f2-4256-b2ad-35cea10743cf --><p><strong>September 2017</strong> — QOF indicators were updated as per the 2017/18 QOF recommendations. </p><p><strong>December 2016</strong> — minor update. Information on a possible drug interaction with bupropion and digoxin has been added to the drug interactions section of this topic, in line with the manufacturer's Summary of Product Characteristics ABPI, 2016.</p><p><strong>August 2014 </strong>— minor update to the text to reflect an update to the Summary of Product Characteristics for NiQuitin® patches that the dose should be reduced or patches discontinued if there is a significant increase in cardiovascular or other effects attributable to nicotine.</p><p><strong>April 2014 </strong>— minor update to the text to reflect an update to the Summary of Product Characteristics for NiQuitin® that seizures have been reported (frequency unknown).</p><p><strong>February 2014 </strong>— minor update to the prescribing information for nicotine gum to reflect an update in the manufacturer's Summary of Product Characteristics about cardiovascular risks.</p><p><strong>January 2014 </strong>— minor update. Formatting errors corrected.</p><p><strong>June 2013</strong> — minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — reviewed. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. Recommendations have been amended as a result of the extended indications for nicotine replacement therapy (NRT). In addition to being used to relieve and/or prevent craving and nicotine withdrawal symptoms in smokers wishing to quit abruptly, NRT can also be used to reduce the amount smoked prior to quitting, to assist smokers who want (or need) to abstain from smoking temporarily (for example during enforced abstinence [such as on a long flight or in hospital] or in the company of non-smokers), and as a safer alternative to smoking.</p><p><strong>November 2016</strong> — minor update. The basis for recommendation for adverse effects of varenicline has been updated with information from a randomised controlled trial, which found that varenicline did not significantly increase the risk of neuropsychiatric events in people with or without a history of psychiatric disorder, compared with nicotine patches or placebo. </p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>March 2011 </strong>— minor update. Missing QOF indicators added. Issued in March 2011.</p><p><strong>October 2009 </strong>— minor update to include new information from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding varenicline and suicidal thoughts and behaviour, and regarding drug interactions with smoking cessation. Issued in October 2009.</p><p><strong>April 2009 </strong>— updated to include the indicators related to smoking cessation in the Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) contract in the <em>Goals and outcome measures </em>section. Issued in May 2009.</p><p><strong>January 2009 </strong>— minor typographical correction. Issued in February 2009.</p><p><strong>August 2008 </strong>— minor update to include updated advice from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding varenicline and suicidal thoughts and behaviour. Issued in August 2008.</p><p><strong>November 2007 to April 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>March 2008 </strong>— Correction to the title of one varenicline prescription. Change in text to read 500 mcg instead of 500 mg.</p><p><strong>July 2007 </strong>— Minor update to text to include new advice from the NICE technology appraisal guidance on the use of varenicline for smoking cessation.</p><p><strong>July 2007 </strong>— Minor update to text, incorporating MHRA (2005) advice, which states that nicotine replacement therapies may be used in combination.</p><p><strong>July to September 2005 </strong>— reviewed. Validated in December 2005 and issued in February 2006.</p><p><strong>May 2002 </strong>— reviewed. Validated in June 2002 and issued in July 2002.</p><p><strong>April 2002 </strong>— updated to include <em>Guidance on the use of nicotine replacement therapy and bupropion for smoking cessation</em>, Technology Appraisal Guidance No. 39, issued by the National Institute for Health and Care Excellence.</p><p><strong>April 2001 </strong>— updated to include the amendment of Schedule 10 to the NHS (General Medical Services) Regulations 1992 permitting the full range of nicotine replacement products to be prescribed on NHS prescriptions.</p><p><strong>October 2000 </strong>— updated to include information and prescriptions for bupropion.</p><p><strong>November 1998 </strong>— written. Validated in March 1999 and issued in May 1999.</p><!-- end field eb1c9020-21f2-4256-b2ad-35cea10743cf --><!-- end item 9075f2c2-0a4d-4f46-9de3-783a3862f4a8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}